Sells in-office fertility treatments and diagnostic devices, sperm-preparation products, and non-surgical permanent birth-control systems to gynecologists, fertility specialists, and medical centers.
10-K for FY2025, filed Mar 31, 2026We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected…View ↗
FemaSeed – Our Artificial Insemination Therapeutic Solution, FemVue – Our Companion Diagnostic for Tubal Evaluation and FemSperm – Our…View ↗
FemBloc – Our Permanent Birth Control Solution and FemChec – Our Companion Diagnostic for Tubal Occlusion Confirmation. FemBloc is our…View ↗
We sell our product to medical centers, including healthcare practitioner offices, primarily through our direct commercial team in the…View ↗
Sells medical products to U.S. medical centers and practitioner offices mainly through its direct commercial team, and to international customers through distributors; customers are typically billed when goods ship and pay within 30 to 60 days.
10-K for FY2025, filed Mar 31, 2026
$2.3M
10-K for FY2025, filed Mar 31, 2026
$2.3M ↗
U.S. medical centers, including practitioner offices, buy primarily through the company’s direct commercial team; international customers buy through distributors.
10-K for FY2025, filed Mar 31, 2026We sell our product to medical centers, including healthcare practitioner offices, primarily through our direct commercial team in the…View ↗
10-K for FY2025, filed Mar 31, 2026
The Company generates revenue from sales directly to U.S. customers and to the Company’s international distributors with all prices in U.S.…View ↗
No. It lost $18.6M in FY2025.
FemaSeed reaches commercialization
The earlier report described FemaSeed as a product candidate in development; the latest report describes it as cleared and commercially sold, alongside FemSperm kits for in-office sperm preparation.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 31, 2026FemaSeed – Our Artificial Insemination Solution. Our artificial insemination solution in development includes our proprietary FemaSeed…View ↗
FemBloc advances beyond development
The earlier report described FemBloc as in development; the latest report says it has regulatory approvals in Europe, the UK and New Zealand, with distribution partnerships in select international markets.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 31, 2026
Competes with Cook Medical, Cooper Surgical, MedGyn Products, Rocket Medical, Dysis Medical, and Guided Therapeutics
10-K for FY2025, filed Mar 31, 2026With respect to our artificial insemination solution, we expect to compete with IUI, IVF/ ICSI and fertility-enhancing pharmaceuticals…View ↗
Loading...